Clinical Trials Logo

Advanced BRAF Mutant Melanoma clinical trials

View clinical trials related to Advanced BRAF Mutant Melanoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02257424 Completed - Clinical trials for Advanced BRAF Mutant Melanoma

Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

BAMM
Start date: October 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The primary purpose of this study is to determine the maximum tolerated dose (MTD) and preliminary safety of hydroxychloroquine (HCQ) when administered in conjunction with oral dabrafenib and trametinib (D+T) in patients with advanced BRAF mutant melanoma.